|
186 Companies |
|
243 Products |
|
243 Products |
|
92 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...4041424344454647484950...5253» |
- cyclophosphamide / Generic mfg.
Trial completion: Stem Cell Transplantation for Patients With Cancers of the Blood (clinicaltrials.gov) - Nov 28, 2012
P2, N=61, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes (clinicaltrials.gov) - Nov 28, 2012
P2, N=38, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- |||| deferasirox tablet for oral suspension / Generic mfg.
Trial completion, MRI: Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload (clinicaltrials.gov) - Nov 27, 2012
P4, N=118, Completed, Sponsor: Novartis
Recruiting --> Completed Recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial initiation date, Combination therapy: NICOLI: Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (clinicaltrials.gov) - Nov 27, 2012
P4, N=4, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Jun 2011 --> Apr 2012
- | Apocept (asunercept) / Apogenix
New P1 trial: APG101 in Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 27, 2012
P1, N=18, Recruiting, Sponsor: Apogenix GmbH
- Enrollment open, Metastases: T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Nov 27, 2012
P1, N=39, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Initiation date: Jun 2011 --> Apr 2012 Suspended --> Recruiting
- | Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed: Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (clinicaltrials.gov) - Nov 27, 2012
P1/2, N=34, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Suspended --> Recruiting Recruiting --> Active, not recruiting
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment change: Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 26, 2012
P1/2, N=0, Withdrawn, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting N=33 --> 0
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed: Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 26, 2012
P1, N=28, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
N=33 --> 0 Recruiting --> Active, not recruiting
- | Jakafi (ruxolitinib) / Novartis, Incyte
New P2 trial: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Nov 20, 2012
P2, N=28, Recruiting, Sponsor: Mayo Clinic
- Trial termination: Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=90, Terminated, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Terminated
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open: Aflibercept in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 19, 2012
P2, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated Completed --> Recruiting
- Enrollment open: APCORD: Cord Blood Transplantation in Severe Aplastic Anemia (clinicaltrials.gov) - Nov 18, 2012
P2, N=26, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Completed --> Recruiting Not yet recruiting --> Recruiting
- | New P1/2 trial: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 18, 2012
P1/2, N=52, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Metastases: Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm (clinicaltrials.gov) - Nov 15, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 15, 2012
P1/2, N=0, Withdrawn, Sponsor: Columbia University
Recruiting --> Active, not recruiting Completed --> Withdrawn
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 15, 2012
P1/2, N=0, Withdrawn, Sponsor: Columbia University
Completed --> Withdrawn N=43 --> 0
- | saridegib oral (IPI 926 oral) / Infinity Pharma
Enrollment change: A Phase 2 Study With IPI-926 in Patients With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=14, Completed, Sponsor: Infinity Pharmaceuticals, Inc.
N=43 --> 0 N=35 --> 14
- | saridegib oral (IPI 926 oral) / Infinity Pharma
Trial completion: A Phase 2 Study With IPI-926 in Patients With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=14, Completed, Sponsor: Infinity Pharmaceuticals, Inc.
N=35 --> 14 Active, not recruiting --> Completed
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment change, Epigenetic controller: Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=41 --> 23
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Epigenetic controller: Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=41 --> 23 Active, not recruiting --> Completed
- | zoledronic acid / Generic mfg.
Trial completion, Tumor cell, Metastases: MACS1295: Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Nov 13, 2012
P4, N=44, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| imatinib / Generic mfg.
Trial completion: Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Nov 13, 2012
P4, N=80, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion: ENACT: A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (clinicaltrials.gov) - Nov 12, 2012
P3, N=6, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dasatinib / Generic mfg.
New P2 trial: NordCML007: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia (clinicaltrials.gov) - Nov 8, 2012
P2, N=35, Recruiting, Sponsor: Norwegian University of Science and Technology
- ||| Bosulif (bosutinib) / Pfizer
Enrollment closed: Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias (clinicaltrials.gov) - Nov 8, 2012
P1/2, N=62, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || azacitidine / Generic mfg.
Enrollment closed, Observational data: Piaza: Non-interventional Study With Azacitidin (Vidaza®) (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=150, Active, not recruiting, Sponsor: iOMEDICO AG
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 7, 2012
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=55 --> 36
- Campath (alemtuzumab) / Sanofi
Clinical: Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders (clinicaltrials.gov) - Nov 7, 2012
P2, N=35, Completed, Sponsor: University of California, San Francisco
N=55 --> 36 Recruiting --> Completed
- peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease (clinicaltrials.gov) - Nov 7, 2012
P1, N=21, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- arsenic trioxide / Generic mfg., decitabine / Generic mfg.
Enrollment change: Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 4, 2012
P2, N=7, Completed, Sponsor: Duke University
Recruiting --> Completed N=60 --> 7
- Trial completion: Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov) - Nov 3, 2012
P=N/A, N=190, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
N=60 --> 7 Active, not recruiting --> Completed
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion: AML02: Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia (clinicaltrials.gov) - Nov 1, 2012
P3, N=238, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
New P2 trial: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Oct 31, 2012
P2, N=74, Recruiting, Sponsor: Indiana University
- ||| RG7112 / Roche
Trial completion: A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. (clinicaltrials.gov) - Oct 31, 2012
P1, N=116, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
New P2 trial: Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. (clinicaltrials.gov) - Oct 29, 2012
P2, N=132, Active, not recruiting, Sponsor: Groupe Francophone des Myelodysplasies
- cyclophosphamide / Generic mfg.
Trial completion: Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders (clinicaltrials.gov) - Oct 23, 2012
P2, N=72, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change: Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=72, Completed, Sponsor: Amgen
Active, not recruiting --> Completed N=250 --> 72
- ||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=72, Completed, Sponsor: Amgen
N=250 --> 72 Active, not recruiting --> Completed
- | Jakafi (ruxolitinib) / Novartis, Incyte, ruxolitinib sustained release (INCB018424 SR) / Incyte
Trial completion: Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients (clinicaltrials.gov) - Oct 21, 2012
P2, N=41, Completed, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| imatinib / Generic mfg., cytarabine / Generic mfg.
Trial completion: Safety and Efficacy of Imatinib Versus Interferon-? Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (clinicaltrials.gov) - Oct 17, 2012
P3, N=1106, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial, Metastases: ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS (clinicaltrials.gov) - Oct 16, 2012
P2, N=20, Recruiting, Sponsor: Ottawa Hospital Research Institute
- ||||| Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment closed: Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients (clinicaltrials.gov) - Oct 16, 2012
P3, N=267, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies (clinicaltrials.gov) - Oct 15, 2012
P2, N=50, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment closed: Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Oct 14, 2012
P2, N=40, Active, not recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | azacitidine / Generic mfg., decitabine / Generic mfg.
Enrollment change, Head-to-Head: Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 12, 2012
P3, N=300, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting N=75 --> 300
- | azacitidine / Generic mfg., decitabine / Generic mfg.
Trial completion, Head-to-Head: Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 12, 2012
P3, N=300, Completed, Sponsor: Seoul National University Hospital
N=75 --> 300 Recruiting --> Completed
- Zamyl (lintuzumab) / Pfizer
Trial termination: Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 10, 2012
P2, N=7, Terminated, Sponsor: Alison Walker
Recruiting --> Completed Not yet recruiting --> Terminated; Drug no longer being supplied by sponsor
- Zamyl (lintuzumab) / Pfizer
Enrollment change: Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 10, 2012
P2, N=7, Terminated, Sponsor: Alison Walker
Not yet recruiting --> Terminated; Drug no longer being supplied by sponsor N=35 --> 7
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=43, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=35 --> 7 N=60 --> 43